Patents by Inventor Robert W. Mays
Robert W. Mays has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11992507Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.Type: GrantFiled: January 23, 2007Date of Patent: May 28, 2024Assignee: ABT HOLDING COMPANYInventors: Robert W. Mays, Robert J. Deans
-
Publication number: 20210299185Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: ApplicationFiled: June 10, 2021Publication date: September 30, 2021Applicants: ABT Holding Company, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert W. MAYS, Robert J. DEANS, David C. HESS, James E. CARROLL, Cesar V. BORLONGAN
-
Publication number: 20200390821Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: August 31, 2020Publication date: December 17, 2020Inventor: Robert W. Mays
-
Patent number: 10758570Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: GrantFiled: April 9, 2018Date of Patent: September 1, 2020Assignee: ABT Holding CompanyInventor: Robert W. Mays
-
Publication number: 20180311287Abstract: The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: March 8, 2016Publication date: November 1, 2018Applicants: ABT Holding Company, Board of Regents of the University of Texas SystemInventors: Charles Samuel COX, Robert W. Mays
-
Publication number: 20180250342Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: April 9, 2018Publication date: September 6, 2018Inventor: Robert W. Mays
-
Patent number: 9937208Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: GrantFiled: June 1, 2011Date of Patent: April 10, 2018Assignee: ABT Holding CompanyInventor: Robert W. Mays
-
Publication number: 20160282336Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: September 17, 2015Publication date: September 29, 2016Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20160256502Abstract: The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: March 8, 2016Publication date: September 8, 2016Applicant: ABT Holding CompanyInventors: Charles Samuel COX, Robert W. Mays
-
Publication number: 20150093364Abstract: The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.Type: ApplicationFiled: December 5, 2014Publication date: April 2, 2015Applicants: ABT Holding Company, Case Western Reserve UniversityInventors: Sarah A. BUSCH, Kevin P. Horn, Robert W. Mays, Jerry Silver
-
Publication number: 20140295442Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20140186307Abstract: The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.Type: ApplicationFiled: October 3, 2013Publication date: July 3, 2014Applicants: Case Western Reserve University, ABT Holding CompanyInventors: Sarah A. BUSCH, Kevin P. Horn, Robert W. Mays, Jerry Silver
-
Patent number: 8460894Abstract: The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated conditions.Type: GrantFiled: June 11, 2009Date of Patent: June 11, 2013Assignee: ABT Holding CompanyInventors: George Mbella Ekema, Pieter W. Faber, Benjamin Philip Faga, Gregory B. Foust, John Joseph Harrington, Paul David Jackson, Robert W. Mays
-
Publication number: 20120009674Abstract: The present invention is directed to the culture of non-embryonic cells, that can differentiate into cell types of more than one embryonic lineage, in culture under conditions that maintain differentiation capacity during expansion; more particularly, culturing non-embryonic cells in the presence of at least one GKS-3 inhibitor, such as BIO.Type: ApplicationFiled: June 30, 2011Publication date: January 12, 2012Applicant: ABT Holding CompanyInventor: Robert W. Mays
-
Publication number: 20110318313Abstract: The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: June 1, 2011Publication date: December 29, 2011Applicants: The Board of Regents of the University of Texas System, ABT Holding CompanyInventors: Charles S. Cox, JR., Robert W. Mays
-
Publication number: 20110305638Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate macrophage activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate macrophage activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency to modulate macrophage activation.Type: ApplicationFiled: March 25, 2011Publication date: December 15, 2011Applicants: Case Western Reserve University, ABT Holding CompanyInventors: Anthony E. Ting, Robert W. Mays, Jason A. Hamilton, Sarah P. Busch, Jerry Silver
-
Publication number: 20110293578Abstract: The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.Type: ApplicationFiled: September 4, 2009Publication date: December 1, 2011Applicants: Case Western Reserve University, ABT Holding CompanyInventors: Sarah A. Busch, Kevin P. Horn, Robert W. Mays, Jerry Silver
-
Publication number: 20110293642Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: ApplicationFiled: June 1, 2011Publication date: December 1, 2011Applicant: ABT Holding CompanyInventor: Robert W. Mays
-
Publication number: 20110212069Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.Type: ApplicationFiled: March 25, 2011Publication date: September 1, 2011Applicant: ABT Holding CompanyInventors: Jason A. Hamilton, Anthony E. Ting, Robert W. Mays
-
Publication number: 20100008890Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.Type: ApplicationFiled: January 23, 2007Publication date: January 14, 2010Applicant: ATHERSYS, INC.Inventors: Robert W. Mays, Robert J. Deans